Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1984 Dec;18(6):831–836. doi: 10.1111/j.1365-2125.1984.tb02552.x

Initial clinical experience with ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor blocker with ISA--a multicentre trial in 59 patients.

B Dahlöf, M Danielson, O Andersson, T Thulin, P Ohman, C Mörlin, J Boberg, B E Karlberg, S Jern, L Hansson
PMCID: PMC1463665  PMID: 6152175

Abstract

The objective of this placebo controlled double-blind multicentre (six centres) trial was to investigate the safety and efficacy of ICI 141,292 (Visacor), a new selective beta 1-adrenoceptor antagonist with modest intrinsic sympathomimetic activity (ISA), in hypertensive patients. Fifty-nine patients with mild essential hypertension were randomized to two of five treatment alternatives (placebo, 50 mg, 100 mg 200 mg or 300 mg of ICI 141,292) each given once daily for 2 weeks with a 4 week placebo period before (run in) and in between (wash out) active periods. Thus, each of the five treatments was evaluated in 20-24 patients. After 2 weeks (24 h after last dose) the reduction in recumbent blood pressure for all doses except 50 mg of ICI 141,292 was statistically significant and in the order of 6/4 mm Hg. Standing systolic blood pressure was reduced in a dose-dependent way but only significant for 200 mg of ICI 141,292 (8 mm Hg). Heart rate changes (delta) less than 4 beats/min) were not statistically significant for any dose. It is concluded that ICI 141,292 was well tolerated and had a significant but weak antihypertensive effect which might be explained by too much beta 1-adrenoceptor ISA.

Full text

PDF
833

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson O., Berglund G., Hansson L., Sannerstedt R., Sivertsson R., Wikstrand J., Wilhelmsen L. Organization and efficacy of an out-patient hypertension clinic. Acta Med Scand. 1978;203(5):391–398. doi: 10.1111/j.0954-6820.1978.tb14894.x. [DOI] [PubMed] [Google Scholar]
  2. Bilski A., Robertson H. H., Wale J. L. A study of the relationship between cardiac beta-adrenoceptor blockade and intrinsic sympathomimetic activity in rats depleted of catecholamines. Clin Exp Pharmacol Physiol. 1979 Jan-Feb;6(1):1–9. doi: 10.1111/j.1440-1681.1979.tb00001.x. [DOI] [PubMed] [Google Scholar]
  3. Brown P., Baddeley H., Read A. E., Davies J. D., McGarry J. Sclerosing peritonitis, an unusual reaction to a beta-adrenergic-blocking drug (practolol). Lancet. 1974 Dec 21;2(7895):1477–1481. doi: 10.1016/s0140-6736(74)90218-9. [DOI] [PubMed] [Google Scholar]
  4. Dahlöf B., Andrén L., Svensson A., Hansson L. Antihypertensive mechanism of beta-adrenoceptor antagonism--the role of beta 2-blockade. J Hypertens Suppl. 1983 Dec;1(2):112–115. [PubMed] [Google Scholar]
  5. Felix R. H., Ive F. A., Dahl M. G. Cutaneous and ocular reactions to practolol. Br Med J. 1974 Nov 9;4(5940):321–324. doi: 10.1136/bmj.4.5940.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kaplan H. R., Smith R. D. Antihypertensive drugs: proposed sites and mechanisms of action. Fed Proc. 1981 Jun;40(8):2268–2274. [PubMed] [Google Scholar]
  7. Man in 't Veld A. J., Schalekamp M. A. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma renin activity, and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol. 1983;5 (Suppl 1):S30–S45. doi: 10.1097/00005344-198300051-00006. [DOI] [PubMed] [Google Scholar]
  8. Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Prichard B. N. Beta-adrenoceptor-blocking agents in the management of hypertension. Cardiology. 1979;64 (Suppl 1):44–87. doi: 10.1159/000170652. [DOI] [PubMed] [Google Scholar]
  10. Prichard B. N., Owens C. W. beta Adrenergic blocking drugs. Pharmacol Ther. 1980;11(1):109–139. doi: 10.1016/0163-7258(80)90069-8. [DOI] [PubMed] [Google Scholar]
  11. Smith H. J., Halliday S. E., Earl D. C., Stribling D. Effects of selective (beta-1 and beta-2) and nonselective beta adrenoceptor antagonists on the cardiovascular and metabolic responses to isoproterenol: comparison with ICI 141,292. J Pharmacol Exp Ther. 1983 Jul;226(1):211–216. [PubMed] [Google Scholar]
  12. Svensson A., Gudbrandsson T., Sivertsson R., Hansson L. Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients. Br J Clin Pharmacol. 1982;13(Suppl 2):259S–267S. doi: 10.1111/j.1365-2125.1982.tb01923.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Wilcox R. G. Randomised study of six beta-blockers and a thiazide diuretic in essential hypertension. Br Med J. 1978 Aug 5;2(6134):383–385. doi: 10.1136/bmj.2.6134.383. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES